Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Safety and efficacy of ab-interno canaloplasty (ABiC) for the treatment of open-angle glaucoma

Poster Details

First Author: M. Khaimi UNITED STATES

Co Author(s):                        

Abstract Details


To investigate the safety and efficacy of ABiC in reducing IOP and glaucoma medication dependence in OAG


Dean McGee Eye Institute, University of Oklahoma, Oklahoma City, Oklahoma, United States of America


This nonrandomized, single center study explored the effect of ABiC or combined cataract surgery-ABiC in adult OAG patients. The primary endpoints included mean IOP and mean number of glaucoma medications over a 12-month period. Secondary endpoints included surgical/postsurgical complications and secondary interventions.


Cohort included 106 subjects with a baseline mean IOP of 19.5 ± 6.6 mmHg which reduced to 15.7 ± 4.4 mm Hg (n=69), 15.0 ± 3.8 mm Hg (n=69), 13.9 ± 1.9 mm Hg (n=20) at 3, 6, 12 months postoperative, respectively. Medication dependency reduced from 2 ± 1 drops preoperatively to 0 ±1 drops at 3, 6, 12 months postoperative, representing a total average decrease of 28.7% in IOP and 100% in medications at 12 months postoperative, versus baseline. In the group of patients who underwent standalone ABiC, mean IOP was reduced by 36.8% from 22.0 ± 8.2 mm Hg preoperatively (n=38) to 13.9 ± 1.6 mm Hg at 12 months postoperative (n=8) with a 50% reduction in medication.


ABiC is safe and effective in achieving IOP reduction and reduces dependence on anti-glaucoma medications in patients with OAG, both as a standalone procedure and combined with phacoemulsification.

Financial Disclosure:


Back to Poster listing